Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease

Experimental Neurology

Volumn 225, Issue 2, 2010, Pages 402-407

  Tallaksen Greene, Sara J ^a,b   Janiszewska, Anita ^a,b   Benton, Kasha ^a,b   Ruprecht, Lech ^a,b   Albin, Roger L ^a,b  

^a VAAAHS   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Excitoxicity; Glutamate; Huntington disease; Striatum

Indexed keywords

4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; [2 (8,9 DIOXO 2,6 DIAZABICYCLO[5.2.0]NON 1(7) EN 2 YL)ETHYL]PHOSPHONIC ACID; IFENPRODIL; IONOTROPIC RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; TRAXOPRODIL; UNCLASSIFIED DRUG; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENOL DERIVATIVE; PIPERIDINE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BRAIN SIZE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG TREATMENT FAILURE; FEMALE; HUNTINGTON CHOREA; MALE; MOTOR PERFORMANCE; NERVE DEGENERATION; NONHUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RECEPTOR BLOCKING; ROTAROD TEST; STRIATE CORTEX; SURVIVAL; TASK PERFORMANCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSGENIC ANIMAL; ANIMAL; ANTAGONISTS AND INHIBITORS; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECTS; HUNTINGTON DISEASE; KAPLAN MEIER METHOD; MOTOR ACTIVITY; MOUSE; ORGAN SIZE; PATHOLOGY; SEX DIFFERENCE; TREATMENT OUTCOME;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; FEMALE; HUNTINGTON DISEASE; KAPLAN-MEIERS ESTIMATE; MALE; MICE; MOTOR ACTIVITY; ORGAN SIZE; PHENOLS; PIPERIDINES; RECEPTORS, N-METHYL-D-ASPARTATE; SEX FACTORS; TREATMENT OUTCOME; KAPLAN-MEIER ESTIMATE;

EID: 77956434789     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.07.015     Document Type: Article

References (56)

1. Bazzett T., Albin R.L. Huntington disease: a model excitotoxic chronic neurodegeneration. Neurodegenerative Brain Disorders 2001, 259-288. T. Palomo, R.J. Beninger, T. Archer (Eds.).
2. Boyce S., Wyatt A., Webb J.K., O'Donnell R., Mason G., Rigby M., Sirinathsinghji D., Hill R.G., Rupniak N.M. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology 1999, 38(5):611-623.
3. Brandt M.R., Cummons T.A., Potestio L., Sukoff S.J., Rosenzweig-Lipson S. Effects of the N-methyl-d-aspartate receptor antagonist perzinfotel [EAA-090; [2-(8, 9-dioxo-2, 6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid] on chemically induced thermal hypersensitivity. J. Pharmacol. Exp. Ther. 2005, 313(3):1379-1386.
4. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 1999, 19(8):3248-3257.
5. Cepeda C., Ariano M.A., Calvert C.R., Flores-Herna ndez J., Chandler S.H., Leavitt B.R., Hayden M.R., Levine M.S. NMDA receptor function in mouse models of Huntington disease. J. Neurosci. Res. 2001, 66:525-539.
6. Chazot P.L., Lawrence S., Thompson C.L. Studies on the subtype selectivity of CP-101,606: evidence for two classes of NR2B-selective NMDA receptor antagonists. Neuropharmacology 2002, 42(3):319-324.
7. Chen N., Luo T., Wellington C., Metzler M., McCutcheon K., Hayden M.R., Raymond L.A. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J. Neurochem. 1999, 72:1890-1898.
8. Coyle J.T., Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 1976, 263(5574):244-246.
9. Fan M.M.Y., Raymond L.A. N-Methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog. Neurobiol. 2007, 81:272-293.
10. Ferrante R.J., Andreassen O.A., Dedeoglu A., Ferrante K.L., Jenkins B.G., Hersch S.M., Beal M.F. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 2002, 22(5):1592-1599.
11. Hansson O., Petersen A., Leist L., Nicotera P., Castilho R.F., Brundin P. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinate acid-induced striatal excitotoxicity. Proc. Natl. Acad. Sci. USA 1999, 96:8727-8732.
12. Hansson O., Guatteo E., Mercuri N.B., Bernardi G., Li X.-J., Castilho R., Brundin P. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioral deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the Huntington gene. Eur. J. Neurosci. 2001, 14:1492-1504.
13. Hardingham G.E. Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochem. Soc. Trans. 2009, 37(Pt 6):1147-1160.
14. Hardingham G.E., Fukunaga Y., Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 2002, 5:405-414.
15. Heng M.Y., Detloff P.J., Albin R.L. Rodent genetic models of Huntington disease. Neurobiol. Dis. 2008, 32(1):1-9.
16. Heng M.Y., Detloff P.J., Wang P.L., Tsien J.Z., Albin R.L. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J. Neurosci. 2009, 29:3200-3205.
17. Imarisio S., Carmichael J., Korolchuk V., Chen C.W., Saiki S., Rose C., Krishna G., Davies J.E., Ttofi E., Underwood B.R., Rubinsztein D.C. Huntington's disease: from pathology and genetics to potential therapies. Biochem. J. 2008, 412(2):191-209.
18. Kew J.N., Kemp J.A. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl.) 2005, 179(1):4-29.
19. Kinney W.A., Abou-Gharbia M., Garrison D.T., Schmid J., Kowal D.M., Bramlett D.R., Miller T.L., Tasse R.P., Zaleska M.M., Moyer J.A. Design and synthesis of [2-(8, 9-dioxo-2, 6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid (EAA-090), a potent N-methyl-d-aspartate antagonist, via the use of 3-cyclobutene-1, 2-dione as an achiral alpha-amino acid bioisostere. J. Med. Chem. 1998, 41(2):236-246.
20. Küppenbender K.D., Standaert D.G., Feuerstein T.J., Penney J.B., Young A.B., Landwehrmeyer G.B. Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum. J. Comp. Neurol. 2000, 419(4):407-421.
21. Leveille F., El Gaamouch F., Gouix E., Lecocq M., Lobner D., Nicole O., Buisson A. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J. 2008, 22:4258-4271.
22. Léveillé F., Papadia S., Fricker M., Bell K.F., Soriano F.X., Martel M.A., Puddifoot C., Habel M., Wyllie D.J., Ikonomidou C., Tolkovsky A.M., Hardingham G.E. Suppression of the intrinsic apoptosis pathway by synaptic activity. J. Neurosci. 2010, 30(7):2623-2635.
23. Levine M.S., Klapstein G.J., Koppel A., Gruen E., Cepeda C., Vargas M.E., Jokel E.S., Carpenter E.M., Zanjani H., Hurst R.S., Efstratiadis A., Zeitlin S., Chesselet M.F. Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 1999, 58:515-532.
24. Li L., Fan M., Icton C.D., Chen N., Leavitt B.R., Hayden M.R., Murphy T.H., Raymond L.A. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiol. Aging 2003, 24:1113-1121.
25. Li L., Murphy T.H., Hayden M.R., Raymond L.A. Enhanced striatal NR2B-containing N-methyl-d-aspartate receptor-mediated synaptic currents in a mouse model of Huntington's disease. J. Neurophysiol. 2004, 92:2738-2746.
26. Lim J., Crespo-Barreto J., Jafar-Nejad P., Bowman A.B., Richman R., Hill D.E., Orr H.T., Zoghbi H.Y. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 2008, 452(7188):713-718.
27. Liu Y., Wong T.P., Aarts M., Rooyakkers A., Liu L., Lai T.W., Wu D.C., Lu J., Tymianski M., Craig A.M., Wang Y.T. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J. Neurosci. 2007, 27(11):2846-2857.
28. Loftis J.M., Janowsky A. The N-methyl-d-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol. Ther. 2003, 97:55-85.
29. Martel M.A., Wyllie D.J., Hardingham G.E. In developing hippocampal neurons, NR2B-containing N-methyl-d-aspartate receptors (NMDARs) can mediate signaling to neuronal survival and synaptic potentiation, as well as neuronal death. Neuroscience 2009, 158:334-343.
30. McGeer E.G., McGeer P.L. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 1976, 263:517-519.
31. Menalled L., El-Khodor B.F., Patry M., Suárez-Fariñas M., Orenstein S.J., Zahasky B., Leahy C., Wheeler V., Yang X.W., MacDonald M., Morton A.J., Bates G., Leeds J., Park L., Howland D., Signer E., Tobin A., Brunner D. Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol. Dis. 2009, 35(3):319-336.
32. Menniti F.S., Pagnozzi M.J., Butler P., Chenard B.L., Jaw-Tsai S.S., Frost White W. CP-101,606, an NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents. Neuropharmacology 2000, 39(7):1147-1155.
33. Milnerwood A.J., Gladding C.M., Pouladi M.A., Kaufman A.M., Hines R.M., Boyd J.D., Ko R.W., Vasuta O.C., Graham R.K., Hayden M.R., Murphy T.H., Raymond L.A. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 2010, 65(2):178-190.
34. Morton A.J., Glynn D., Leavens W., Zheng Z., Faull R.L., Skepper J.N., Wight J.M. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol. Dis. 2009, 33(3):331-341.
35. Mott D.D., Doherty J.J., Zhang S., Washburn M.S., Fendley M.J., Lyuboslavsky P., Traynelis S.F., Dingledine R. Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat. Neurosci. 1998, 1(8):659-667.
36. Murray F., Kennedy J., Hutson P.H., Elliot J., Huscroft I., Mohnen K., Russell M.G., Grimwood S. Modulation of [3H]MK-801 binding to NMDA receptors in vivo and in vitro. Eur. J. Pharmacol. 2000, 397(2-3):263-270.
37. Nutt J.G., Gunzler S.A., Kirchhoff T., Hogarth P., Weaver J.L., Krams M., Jamerson B., Menniti F.S., Landen J.W. Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Mov. Disord. 2008, 23(13):1860-1866.
38. Okamoto S., Pouladi M.A., Talantova M., Yao D., Xia P., Ehrnhoefer D.E., Zaidi R., Clemente A., Kaul M., Graham R.K., Zhang D., Vincent Chen H.S., Tong G., Hayden M.R., Lipton S.A. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 2009, 15(12):1407-1413.
39. Orr H.T., Zoghbi H.Y. Trinucleotide repeat disorders. Annu. Rev. Neurosci. 2007, 30:575-621.
40. Papadia S., Soriano F.X., Léveillé F., Martel M.A., Dakin K.A., Hansen H.H., Kaindl A., Sifringer M., Fowler J., Stefovska V., McKenzie G., Craigon M., Corriveau R., Ghazal P., Horsburgh K., Yankner B.A., Wyllie D.J., Ikonomidou C., Hardingham G.E. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat. Neurosci. 2008, 11(4):476-487.
41. Preskorn S.H., Baker B., Kolluri S., Menniti F.S., Krams M., Landen J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol. 2008, 28(6):631-637.
42. Rosas H.D., Salat D.H., Lee S.Y., Zaleta A.K., Pappu V., Fischl B., Greve D., Hevelone N., Hersch S.M. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008, 131(Pt 4):1057-1068.
43. Shehadeh J., Fernandes H.B., Zeron Mullins M.M., Graham R.K., Leavitt B.R., Hayden M.R., Raymond L.A. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol. Dis. 2006, 21:392-403.
44. Skolnick P., Popik P., Trullas R. Glutamate-based antidepressants: 20years on. Trends Pharmacol. Sci. 2009, 30(11):563-569.
45. Stack E.C., Kubilus J.K., Smith K., Cormier K., Del Signore S.J., Guelin E., Ryu H., Hersch S.M., Ferrante R.J. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J. Comp. Neurol. 2005, 490(4):354-370.
46. Stack E.C., Dedeoglu A., Smith K.M., Cormier K., Kubilus J.K., Bogdanov M., Matson W.R., Yang L., Jenkins B.G., Luthi-Carter R., Kowall N.W., Hersch S.M., Beal M.F., Ferrante R.J. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. J. Neurosci. 2007, 27(47):12908-12915.
47. Standaert D.G., Friberg I.K., Landwehrmeyer G.B., Young A.B., Penney J.B. Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat. Brain Res. Mol. Brain Res. 1999, 64(1):11-23.
48. Stanika R.I., Pivovarova N.B., Brantner C.A., Watts C.A., Winters C.A., Andrews S.B. Coupling diverse routes of calcium entry to mitochondrial dysfunction and glutamate excitotoxicity. Proc. Natl. Acad. Sci. USA 2009, 106(24):9854-9859.
49. Sun L., Chiu D., Kowal D., Simon R., Smeyne M., Zukin R.S., Olney J., Baudy R., Lin S. Characterization of two novel N-methyl-d-aspartate antagonists: EAA-090 (2-[8, 9-dioxo-2, 6-diazabicyclo [5.2.0]non-1(7)-en2-yl]ethylphosphonic acid) and EAB-318 (R-alpha-amino-5-chloro-1-(phosphonomethyl)-1H-benzimidazole-2-propanoic acid hydrochloride). J. Pharmacol. Exp. Ther. 2004, 310(2):563-570.
50. Tovar K.R., Westbrook G.L. The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J. Neurosci. 1999, 19(10):4180-4188.
51. Vonsattel J.P., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 1998, 57(5):369-384.
52. Warby S.C., Graham R.K., Hayden M.R. Huntington disease http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=huntington.
53. Waxman E.A., Lynch D.R. N-methyl-d-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist 2005, 11:37-49.
54. Zeron M.M., Chen N., Moshaver A., Lee A.T., Wellington C.L., Hayden M.R., Raymond L.A. Mutant huntingtin enhances excitotoxic cell death. Mol. Cell. Neurosci. 2001, 17:41-53.
55. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., Raymond L.A. Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002, 33:849-860.
56. Zeron M.M., Fernandes H.B., Krebs C., Shehadeh J., Wellington C.L., Leavitt B.R., Baimbridge K.G., Hayden M.R., Raymond L.A. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Mol. Cell. Neurosci. 2004, 25:469-479.